Multiple Sclerosis Clinical Trials Near You

Multiple sclerosis (MS) trials in 2026 are focused on three goals: stopping inflammatory relapses, preventing progressive disability accumulation, and repairing existing myelin damage. Bruton's tyrosine kinase (BTK) inhibitors — tolebrutinib, fenebrutinib, and evobrutinib — are the most anticipated drug class, targeting both B cells in the periphery and microglia within the brain. Unlike current treatments, BTK inhibitors cross the blood-brain barrier to address the compartmentalized neuroinflammation driving progressive MS.

Remyelination therapies aim to repair damaged nerve fibers rather than just preventing new damage. Opicinumab (anti-LINGO-1) and clemastine (a repurposed antihistamine) are in trials testing whether they can restore myelin sheaths and improve neurological function. Anti-CXCR2 compounds are also being tested to promote oligodendrocyte precursor cell maturation.

High-efficacy early treatment strategies are gaining support from long-term data: trials comparing early use of high-efficacy therapies (ocrelizumab, ofatumumab, natalizumab) versus traditional step-up approaches show significantly less disability accumulation over 10+ years.

For progressive MS, the pipeline includes neuroprotective agents (ibudilast, simvastatin, lipoic acid) targeting neurodegeneration, alongside hematopoietic stem cell transplantation (HSCT) trials for aggressive relapsing MS.

Patient considerations: MS trials require a confirmed diagnosis with documented relapses or MRI activity. Expect regular MRI scans (brain and spinal cord), neurological exams (EDSS scoring), and cognitive assessments. Many trials require a washout period from prior disease-modifying therapies — plan timing carefully with your neurologist. Progressive MS trials often have longer endpoints (12–24 months) due to the slow nature of disability accumulation.